18.07.2013 • News

Monsanto to Withdraw EU Approval Requests For New GMO Crops

Monsanto said on Wednesday it will withdraw all pending approval requests to grow new types of genetically modified crops in the European Union, due to the lack of commercial prospects for cultivation there.

"We will be withdrawing the approvals in the coming months," Monsanto's President and Managing Director for Europe, Jose Manuel Madero, told Reuters by telephone.

Madero said the decision would allow the company to focus on growing its conventional seeds business in Europe, as well as securing EU approvals to import its genetically modified crop varieties widely grown in the United States and South America.

The decision covered five EU approval requests to grow genetically modified maize, plus one soybean and one sugar beet. The company said it would not withdraw its application to renew the approval for its insect-resistant MON810 maize - the only GMO crop currently cultivated commercially in Europe.

A spokesman for the European Commission, which manages the EU's GMO approval system, confirmed that Monsanto had informed it of its intention to withdraw the applications.

The move reflects the frustration felt by many biotech companies towards the EU's approval system for GMOs. Decisions routinely face years of delays, and only three varieties have ever been given the green light for cultivation.

While Monsanto's MON810 maize has been approved for cultivation throughout the EU, several countries including France, Germany and most recently Italy have imposed national bans, driven by strong public opposition to the technology.

Last year, German biotech producer BASF halted the development of genetically modified crops in Europe and moved all of its European GMO research operations to the United States.

Despite public hostility to genetically modified foods, Europe is one of the world's major buyers of biotech grain, importing more than 30 million tonnes of mostly GM animal feed each year for its livestock industry.

 

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.